WillItSurvive
Pharma and healthcare groups · subsidiary of Nirayu Limited (holding company of Amin family); Alembic Ltd. retains ~29% stake as legacy parent conglomerate post-2010 demerger · India

Alembic Pharmaceuticals

alembicpharmaceuticals.com ↗

119-year-old Indian generic drugmaker pivoting into US branded products.

Protection under test
Assessed 25 July 2026 · Evidence as of 25 July 2026
Something worth protecting exists and is being tested right now.
On the recordSince 25 July 2026 · Checkable from Aug 2026 · Every call on the record Checkpoint: Q1 FY27 earnings showing tariff impact and Pivya/semaglutide US branded ramp
The call

Alembic stays profitable on its generics base while betting its US branded launches and FDA remediation timeline decide whether it grows past that base or stalls in it.

Alembic makes and sells affordable copies of brand-name drugs across 90+ countries and runs 10 factories with 244 US approvals, generating steady cash. It is hard to replace because building new drug factories and getting government permission takes years and billions of dollars, but it faces two big problems right now: the US Food and Drug Administration found issues at one of its factories in July 2026 that could slow down new drug approvals for 6 to 24 months, and President Trump announced tariffs that could make its US business much more expensive starting August 2026 (the US is its fastest-growing market at 21% growth per year). The company's only real chance to grow is if its two new branded drugs, Pivya and a semaglutide pen, succeed in the US market by mid-2027, but that is unproven and faces competition from much larger rivals like Sun Pharma, Aurobindo, and Lupin.

Why
01
AI pressure: None apparent. AI doesn't replace FDA plant certifications or ANDA filings; no AI lab or agent competes in generic drug manufacturing yet. Could AI do the core job? Unlikely.
02
Bigger players: Sun Pharma, Aurobindo Pharma, Lupin, Dr. Reddy's, Cipla, Teva, Viatris, Sandoz. Larger rivals already sell the same generic molecules at greater scale; Aurobindo just bought Lannett for $250M to add more. Could a giant copy it? Probably.
03
What protects it. 244 FDA-approved ANDAs, 10 plants, distribution in 90+ countries, and steady India branded and API revenue cushioning any single market hit.
What would change this call
Status of FDA Warning Letter at Vadodara facility by mid-2027. Shows whether GCP deficiencies are resolved or escalate toward an import alert.
US tariff enforcement level after Aug 2026 on Alembic's generics. Reveals how much margin pressure hits Alembic's fastest-growing US segment.
Pivya and semaglutide pen US sales figures reported in Q1-Q2 FY27 results. Tests whether Alembic's branded pivot can offset generics commoditization.
Key numbers
  • FY26 revenue Rs 7,345 crore, net profit Rs 675 crore (31 Mar 2026)
  • 244 cumulative USFDA ANDA approvals (20 Jul 2026)
  • Q1 FY26 profit Rs 154 crore, up 15% YoY (30 Jun 2025)
Named risks
  • FDA Warning Letter (10 Jul 2026) on GCP deficiencies at Vadodara Bioequivalence Facility could delay ANDA filings. Severity: high
  • Trump-announced US tariff on generic drug imports escalating to 100% then 200% after Aug 2028. Severity: high
  • Structural tender-based price erosion in commodity generics squeezes margins against larger peers. Severity: medium
  • Unproven execution of US branded pivot (Pivya, semaglutide pen) facing well-capitalized rivals in same niche. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Sun Pharmaceutical Industrieslosing toSun Pharma market cap ~25-30x Alembic's as of 21 Jul 2026
Aurobindo Pharmagaining onAurobindo's $250M Lannett acquisition FTC-approved Jun 2026 expands its US footprint
Lupin LtdcontestingBoth pursuing US branded specialty and GLP-1 generic pivots as of mid-2026
Dr. Reddy's LaboratoriescontestingLarger peer competing in same US generics and branded specialty space
Cipla Ltdlosing toCipla revenue ~$3.1B with ~51,700 employees, far larger scale than Alembic
Questions people ask
Is Alembic Pharmaceuticals profitable in 2026?
Yes. Alembic Pharmaceuticals reported FY26 (year ended 31 Mar 2026) consolidated revenue of ₹7,345 crore and net profit of ₹675 crore, with Q4 FY26 PAT up 29% YoY to ₹203 crore on a 25% pre-R&D EBITDA margin, per its 15 May 2026 press release.
Who is Alembic Pharmaceuticals' biggest competitor?
Sun Pharmaceutical Industries is the dominant rival, with a market cap roughly 25 to 30 times Alembic's as of 21 Jul 2026 per ETMoney. Other peers include Aurobindo Pharma, Lupin, Dr. Reddy's, and Cipla, all chasing the same US branded generics and GLP-1 opportunities.
Could AI replace Alembic Pharmaceuticals?
Unlikely. Alembic's core moat, 244 cumulative USFDA ANDA approvals as of 20 Jul 2026, 10 manufacturing plants, and distribution in 90+ countries, rests on physical manufacturing and regulatory certification that AI does not substitute. No public evidence shows Alembic deploying AI in its operations.
What is the FDA Warning Letter issue at Alembic Pharmaceuticals?
The USFDA issued a Warning Letter dated 10 Jul 2026 to Alembic's Bioequivalence Facility in Vadodara over informed-consent and Good Clinical Practice deficiencies found during a March 2025 inspection, under 21 CFR 312/50, per FDA.gov.
Will Trump's tariffs hurt Alembic Pharmaceuticals?
Potentially. A phased US tariff plan announced around 21 Jul 2026 sets 0% for 24 months from 1 Aug 2026, then 100%, then 200% on imported generics. Alembic's US segment, about 30% of FY26 revenue and its fastest-growing region, is directly exposed.
Who owns Alembic Pharmaceuticals?
Alembic Pharmaceuticals is publicly listed on the BSE and NSE (ticker APLLTD, code 533573), controlled by the Amin family. Parent conglomerate Alembic Ltd. holds roughly 29% of shares, and Chirayu Amin serves as Executive Chairman and CEO.
Timeline
  • 2026-07-23ET Manufacturing reports Trump 200% tariff threat risk to Indian pharma including Alembic
  • 2026-07-21Trump announces phased 0%-100%-200% tariff plan on generic drug imports
  • 2026-07-20Alembic reaches 244 cumulative USFDA ANDA approvals (224 final, 20 tentative)
  • 2026-07-10USFDA issues Warning Letter to Alembic's Vadodara Bioequivalence Facility
  • 2026-06Alembic agrees to acquire 45% stake in 17989377 Canada, Inc.
  • 2026-05-17Alembic outlines FY27 US branded push, targets semaglutide pen for Q2 FY27
  • 2026-05-15Alembic reports Q4 FY26 results: revenue ₹1,848 crore, PAT ₹203 crore
  • 2026-02-06Alembic soft-launches Pivya (pivmecillinam) in the US branded market
  • 2025-08-06Alembic reports Q1 FY26 results: revenue ₹1,711 crore, profit ₹154 crore
  • 2011-09-20Alembic Pharmaceuticals Limited lists on BSE and NSE post 2010 demerger
Revision history
25 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
SolventumNovo NordiskBaxter International
More in Pharma and healthcare groups →
Sources